Section of Legal Medicine of Milan, University of Milan, Via Luigi Mangiagalli 37, 20133, Milan, Italy.
Department of Biomedical Sciences for Health, University of Milan, Via Luigi Mangiagalli 37, 20133, Milan, Italy.
Int J Legal Med. 2024 Nov;138(6):2507-2522. doi: 10.1007/s00414-024-03290-4. Epub 2024 Jul 15.
Hereditary connective tissue disorders (HCTDs) are a heterogeneous group of inherited diseases. These disorders show genetic mutations with loss of function of primary components of connective tissue, such as collagen and elastic fibers. There are more than 200 conditions that involve hereditary connective tissue disorders, while the most known are Marfan syndrome, Osteogenesis Imperfecta, and Ehlers-Danlos syndromes. These disorders need continuous updates, multidisciplinary skills, and specific methodologic evaluations sharing many medicolegal issues. Marfan syndrome and Ehlers-Danlos syndromes show a high risk of early sudden death. As a consequence of this, postmortem genetic testing can identify novel genotype-phenotype correlations which help the clinicians to assess personalized cardiovascular screening programs among the ill subjects. Genetic testing is also essential to identify children suffering from Osteogenesis Imperfecta, especially when a physical abuse is clinically suspected. However, this is a well-known clinical problem even though there are still challenges to interpret genetic data and variants of unknown significance due to the current extensive use of new genetic/genomic techniques. Additionally, the more significant applications and complexities of genomic testing raise novel responsibilities on the clinicians, geneticists, and forensic practitioners as well, increasing potential liability and medical malpractice claims. This systematic review provides a detailed overview on how multidisciplinary skills belonging to clinicians, medicolegal consultants, radiologists, and geneticists can cooperate to manage HCTDs from autopsy or clinical findings to genetic testing. Thus, technical aspects need to be addressed to the medicolegal community since there is no consensus works or guidelines which specifically discuss these issues.
遗传性结缔组织疾病(HCTD)是一组异质性遗传性疾病。这些疾病表现为结缔组织主要成分(如胶原和弹性纤维)的功能丧失的基因突变。有 200 多种疾病涉及遗传性结缔组织疾病,其中最著名的是马凡综合征、成骨不全症和埃勒斯-当洛斯综合征。这些疾病需要不断更新,多学科技能,以及特定的方法学评估,涉及许多医学法律问题。马凡综合征和埃勒斯-当洛斯综合征表现出早期猝死的高风险。因此,尸检后的基因检测可以识别新的基因型-表型相关性,帮助临床医生在患病个体中评估个性化的心血管筛查计划。基因检测对于识别患有成骨不全症的儿童也很重要,尤其是在临床上怀疑有身体虐待时。然而,尽管由于当前广泛使用新的遗传/基因组技术,解释遗传数据和意义不明的变异仍然存在挑战,但这是一个众所周知的临床问题。此外,基因组检测的更重要应用和复杂性也给临床医生、遗传学家和法医从业者带来了新的责任,增加了潜在的责任和医疗事故索赔。本系统评价详细概述了多学科技能如何属于临床医生、医学法律顾问、放射科医生和遗传学家,以从尸检或临床发现到基因检测管理 HCTD。因此,需要向医学法律界提出技术方面的问题,因为目前没有专门讨论这些问题的共识工作或指南。